{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:00:18Z","timestamp":1781060418940,"version":"3.54.1"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ctrv.2026.103158","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T14:44:12Z","timestamp":1779029052000},"page":"103158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Central nervous system and leptomeningeal metastases in patients with HER2-positive breast cancer: A comprehensive review and therapeutic algorithm proposal"],"prefix":"10.1016","volume":"147","author":[{"given":"Aldo","family":"Caltavituro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Buonaiuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Longobardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Trasacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Di","family":"Grazia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pacelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine De","family":"Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelino De","family":"Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Laakmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor Vasconcelos","family":"de Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rio","family":"Fontes-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"van Ramshorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkmar","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Agostinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Linn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo De","family":"Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Schettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103158_b0005","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0002-9440(10)61180-7","article-title":"Breast cancer metastasis to the central nervous system","volume":"167","author":"Weil","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2026.103158_b0010","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.6004\/jnccn.2013.0132","article-title":"Central nervous system cancers","volume":"11","author":"Nabors","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2026.103158_b0015","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12035-014-9023-z","article-title":"Pathogenesis of breast cancer metastasis to brain: a comprehensive approach to the signaling network","volume":"53","author":"Tayyeb","year":"2016","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.ctrv.2026.103158_b0020","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1158\/0008-5472.CAN-17-2748","article-title":"Perspective on circulating tumor cell clusters: why it takes a village to metastasize","volume":"78","author":"Giuliano","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103158_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.716504","article-title":"TAMs in brain metastasis: molecular signatures in mouse and man","volume":"12","author":"Schulz","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2026.103158_b0030","first-page":"187","article-title":"miR-623 targets metalloproteinase-1 and attenuates extravasation of brain metastatic triple-negative breast cancer cells","volume":"14","author":"Hammash","year":"2022","journal-title":"Breast Cancer: Targets Therapy"},{"key":"10.1016\/j.ctrv.2026.103158_b0035","doi-asserted-by":"crossref","first-page":"7087","DOI":"10.3390\/ijms24087087","article-title":"Adhesion to the brain endothelium selects breast cancer cells with brain metastasis potential","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103158_b0040","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.3390\/cancers12123765","article-title":"Breast cancer stem cells: biomarkers, identification and isolation methods, regulating mechanisms, cellular origin, and beyond","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103158_b0045","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10585-012-9457-5","article-title":"Tumor microenvironment: a main actor in the metastasis process","volume":"29","author":"Spano","year":"2012","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ctrv.2026.103158_b0050","doi-asserted-by":"crossref","DOI":"10.20517\/2394-4722.2021.37","article-title":"Breast-to-brain metastasis: a focus on the pre-metastatic niche","author":"Malone","year":"2021","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.ctrv.2026.103158_b0055","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdg300","article-title":"Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival","volume":"14","author":"Miller","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0060","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO\u2013ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102860","article-title":"Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer","volume":"132","author":"M\u00fcller","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2026.103158_b0070","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","article-title":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort","volume":"121","author":"Darlix","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103158_b0075","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41588-020-0628-z","article-title":"Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases","volume":"52","author":"Hu","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2026.103158_b0080","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","article-title":"Tumor metastasis: molecular insights and evolving paradigms","volume":"147","author":"Valastyan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2026.103158_b0085","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","article-title":"Subtypes of breast cancer show preferential site of relapse","volume":"68","author":"Smid","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103158_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105507","article-title":"Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications","volume":"10","author":"Griguolo","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103158_b0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13058-017-0844-3","article-title":"Cooperation of neurotrophin receptor TrkB and Her2 in breast cancer cells facilitates brain metastases","volume":"19","author":"Choy","year":"2017","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103158_b0100","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/bcr2603","article-title":"HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer","volume":"12","author":"Da Silva","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103158_b0105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11060-011-0664-8","article-title":"Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment","volume":"106","author":"Kim","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2023.103583","article-title":"Evolving treatments and outcomes in HER2-positive metastatic breast cancer: data from the GIM14\/BIOMETA study","volume":"72","author":"Di Maio","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2026.103158_b0120","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10585-017-9860-z","article-title":"Neurosurgical management of brain metastases","volume":"34","author":"Ferguson","year":"2017","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ctrv.2026.103158_b0125","doi-asserted-by":"crossref","first-page":"8708","DOI":"10.3390\/ijms14058708","article-title":"Surgical resection of brain metastases\u2014impact on neurological outcome","volume":"14","author":"Sch\u00f6del","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103158_b0130","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1002\/cam4.3402","article-title":"Surgical resection of symptomatic brain metastases improves the clinical status and facilitates further treatment","volume":"9","author":"Sch\u00f6del","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2026.103158_b0135","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0140","article-title":"Management of brain metastasis. Surgical resection versus stereotactic radiotherapy: a meta-analysis","volume":"4","author":"Krist","year":"2022","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ctrv.2026.103158_b0145","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/neuonc\/nox195","article-title":"Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults","volume":"20","author":"Wilke","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0150","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/jama.2026.0076","article-title":"Treatment for brain metastases with stereotactic radiation vs hippocampal-avoidance whole brain radiation","volume":"335","author":"Aizer","year":"2026","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ctrv.2026.103158_b0155","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0160","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2014.57.2909","article-title":"Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial","volume":"32","author":"Gondi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0165","article-title":"Advancing beyond the hippocampus to preserve cognition for patients with brain metastases: dosimetric results from a phase 2 trial of memory-avoidance whole brain radiation therapy","volume":"9","author":"Perlow","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0170","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103158_b0175","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases","volume":"295","author":"Aoyama","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ctrv.2026.103158_b0180","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0185","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1227\/NEU.0000000000000707","article-title":"Estimating the additive benefit of surgical excision to stereotactic radiosurgery in the management of metastatic brain disease","volume":"76","author":"Quigley","year":"2015","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ctrv.2026.103158_b0190","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0195","doi-asserted-by":"crossref","DOI":"10.1001\/jama.280.17.1485","article-title":"Postoperative radiotherapy in the treatment of single metastases to the brain","volume":"280","author":"Patchell","year":"1998","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ctrv.2026.103158_b0200","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.2018.78.6186","article-title":"Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504): a phase III, noninferiority, randomized controlled trial","volume":"36","author":"Kayama","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0205","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.radonc.2019.08.024","article-title":"Post-operative stereotactic radiosurgery following excision of brain metastases: a systematic review and meta-analysis","volume":"142","author":"Akanda","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0210","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0215","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0220","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ijrobp.2021.05.124","article-title":"Preoperative radiosurgery for resected brain metastases: the PROPS-BM multicenter cohort study","volume":"111","author":"Prabhu","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2026.103158_b0225","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.adro.2019.11.001","article-title":"A cohort study of stereotactic radiosurgery results for patients with 5 to 15 versus 2 to 4 brain metastatic tumors","volume":"5","author":"Yamamoto","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0230","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3171\/2014.8.GKS141421","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2\u20139 versus 10 or more tumors","volume":"121","author":"Yamamoto","year":"2014","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ctrv.2026.103158_b0235","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/neuros\/nyy276","article-title":"Clinical outcomes of upfront stereotactic radiosurgery alone for patients with 5 to 15 brain metastases","volume":"85","author":"Hughes","year":"2019","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ctrv.2026.103158_b0240","article-title":"A dutch phase III randomized multicenter trial: whole brain radiotherapy versus stereotactic radiotherapy for 4\u201310 brain metastases","volume":"3","author":"Hartgerink","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ctrv.2026.103158_b0245","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.ijrobp.2020.07.2108","article-title":"Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: a phase III randomized controlled trial","volume":"108","author":"Li","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2026.103158_b0605","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0250","doi-asserted-by":"crossref","first-page":"e1557","DOI":"10.1016\/j.wneu.2018.11.100","article-title":"Neurosurgical resection and stereotactic radiation versus stereotactic radiation alone in patients with a single or solitary brain metastasis","volume":"122","author":"Lamba","year":"2019","journal-title":"World Neurosurg"},{"key":"10.1016\/j.ctrv.2026.103158_b0255","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1227\/NEU.0000000000001096","article-title":"Comparing preoperative with postoperative stereotactic radiosurgery for resectable brain metastases","volume":"79","author":"Patel","year":"2016","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ctrv.2026.103158_b0260","first-page":"793","article-title":"Neoadjuvant stereotactic radiosurgery for large brain metastases: an international, multicenter","volume":"97","author":"Higazy","year":"2025","journal-title":"Single-Arm Phase II Trial Neurosurgery"},{"key":"10.1016\/j.ctrv.2026.103158_b0265","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/neuonc\/noad188","article-title":"The dilemma of radiation necrosis from diagnosis to treatment in the management of brain metastases","volume":"26","author":"Mayo","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0270","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.2025.43.16_suppl.1039","article-title":"Risk of radiation necrosis with concurrent antibody-drug conjugates and radiotherapy in HER2-positive breast cancer with brain metastases: a meta-analysis","volume":"43","author":"Sarfraz","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104691","article-title":"Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort","volume":"85","author":"Visani","year":"2026","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2026.103158_b0280","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s10143-025-04056-1","article-title":"Timing matters: radiation necrosis risk of antibody-drug conjugates (ADCs) combined with radiation therapy in breast cancer brain metastases: a systematic review and comparative meta-analysis","volume":"49","author":"Zare","year":"2026","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.ctrv.2026.103158_b0285","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11060-024-04681-8","article-title":"Impact of concurrent antibody\u2013drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study","volume":"168","author":"Koide","year":"2024","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0290","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S1470-2045(23)00534-X","article-title":"International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations","volume":"25","author":"Meattini","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0295","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103158_b0300","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1016\/j.annonc.2023.09.554","article-title":"377O a pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03","volume":"34","author":"Hurvitz","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0305","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1158\/2159-8290.CD-22-0837","article-title":"Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis","volume":"12","author":"Jerusalem","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103158_b0310","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdu486","article-title":"Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA","volume":"26","author":"Krop","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0315","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial","volume":"31","author":"Montemurro","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0320","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103158_b0115","unstructured":"National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers. NCCN Clinical Practice Guidelines in Oncology. Version 3.2025. 2025. Available at: NCCN.org. Accessed [15\/04\/2026]. n.d."},{"key":"10.1016\/j.ctrv.2026.103158_b0325","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/annonc\/mdu133","article-title":"Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA","volume":"25","author":"Swain","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0340","unstructured":"Metzger, O. (2025, December 9\u201312). Central Nervous System Outcomes from the Phase III PATINA Trial (AFT-38) [Conference presentation]. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, United States. Retrieved December 15, 2025. n.d."},{"key":"10.1016\/j.ctrv.2026.103158_b0430","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0445","article-title":"HER2CLIMB-05: a phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2+ metastatic breast cancer","author":"Dieras","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0610","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41523-023-00587-2","article-title":"Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data","volume":"9","author":"Lin","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103158_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102924","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial","volume":"9","author":"Hurvitz","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103158_b0385","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103158_b0390","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial","volume":"25","author":"P\u00e9rez-Garc\u00eda","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0400","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41523-023-00584-5","article-title":"Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and\/or leptomeningeal disease (ROSET-BM)","volume":"9","author":"Niikura","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103158_b0395","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103158_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103207","article-title":"185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07)","volume":"9","author":"Anders","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103158_b0475","doi-asserted-by":"crossref","first-page":"e1327","DOI":"10.1002\/onco.13830","article-title":"Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial","volume":"26","author":"Hurvitz","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103158_b0355","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.annonc.2024.07.245","article-title":"Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: translational breast cancer research consortium trial 022","volume":"35","author":"Freedman","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0455","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2015.63.0343","article-title":"Translational breast cancer research consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2\u2013positive breast cancer and brain metastases","volume":"34","author":"Freedman","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0465","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0620","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2014.57.1794","article-title":"CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2\u2013positive metastatic breast cancer","volume":"33","author":"Pivot","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0330","doi-asserted-by":"crossref","unstructured":"Loibl S, Metzger O, Mandrekar SJ, Mundhenke C, Seiler S, Valagussa P, et al. PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)\/HER2-positive metastatic breast cancer (MBC). Annals of Oncology 2018;29:viii121. https:\/\/doi.org\/10.1093\/annonc\/mdy272.357.","DOI":"10.1093\/annonc\/mdy272.357"},{"key":"10.1016\/j.ctrv.2026.103158_b0335","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa2511218","article-title":"Palbociclib for hormone-receptor\u2013positive, HER2-positive advanced breast cancer","volume":"394","author":"Metzger","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103158_b0345","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1470-2045(13)70017-2","article-title":"CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)","volume":"14","author":"Pestalozzi","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0350","volume":"80","author":"Piccart","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103158_b0360","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103158_b0365","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103158_b0370","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103158_b0380","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","author":"Tolaney","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103158_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101437","article-title":"249P a retrospective review of patients receiving trastuzumab deruxtecan across five centres in Ireland with a subgroup analysis of patients with CNS involvement assessing response in the CNS","volume":"8","author":"Murphy","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103158_b0410","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","author":"Loibl","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103158_b0415","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood\u2013brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctrv.2026.103158_b0420","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","article-title":"Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models","volume":"19","author":"Kulukian","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2026.103158_b0425","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2018.05.004","article-title":"Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer","volume":"67","author":"Duchnowska","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2026.103158_b0435","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0440","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-GS01-10","article-title":"Abstract GS01-10: HER2CLIMB-02: randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer","volume":"84","author":"Hurvitz","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103158_b0450","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0460","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103158_b0470","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","article-title":"Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2\u2013positive breast cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0480","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/tbcr-20-25","article-title":"Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study","volume":"1","author":"Yan","year":"2020","journal-title":"Transl Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103158_b0485","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(21)00716-6","article-title":"Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial","volume":"23","author":"Yan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0490","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-PS8-01","article-title":"Abstract PS8-01: ZN-1041, a potential best-in-class BBB Penetrable HER2 inhibitor, has high antitumor activity in patients with Breast Cancer with CNS metastases","volume":"31","author":"Zhu","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103158_b0495","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13058-023-01679-4","article-title":"Preclinical and clinical activity of DZD1516, a full blood\u2013brain barrier-penetrant, highly selective HER2 inhibitor","volume":"25","author":"Zhang","year":"2023","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103158_b0500","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S1470-2045(15)00373-3","volume":"16","author":"Cort\u00e9s","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0505","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3340\/jkns.2012.52.3.193","article-title":"Incidence and risk factors for leptomeningeal carcinomatosis in breast cancer patients with parenchymal brain metastases","volume":"52","author":"Jung","year":"2012","journal-title":"J Korean Neurosurg Soc"},{"key":"10.1016\/j.ctrv.2026.103158_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO\u2013ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103158_b0515","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.bulcan.2025.02.029","article-title":"M\u00e9tastases leptom\u00e9ning\u00e9es dans le cancer du sein\u2013\u00c9tat des lieux et perspectives","volume":"112","author":"Larrouquere","year":"2025","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ctrv.2026.103158_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104433","article-title":"Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC","volume":"81","author":"Laakmann","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2026.103158_b0525","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jamaoncol.2025.3007","article-title":"Proton craniospinal irradiation for patients with leptomeningeal metastasis","volume":"11","author":"Yang","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0530","article-title":"Early outcomes from proton craniospinal irradiation for leptomeningeal metastasis from solid tumors","volume":"10","author":"Lam","year":"2025","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0535","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijrobp.2013.01.014","article-title":"Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma","volume":"86","author":"Brown","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2026.103158_b0540","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO\u2013ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0545","first-page":"i6","article-title":"LPTO-02. Intrathecal (IT) trastuzumab (t) for the treatment of leptomeningeal disease (LM) in patients (PTS) with human epidermal receptor-2 positive (HER2+) cancer: a multicenter phase 1\/2 study","volume":"1","author":"Kumthekar","year":"2019","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ctrv.2026.103158_b0550","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10549-019-05170-7","article-title":"Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy","volume":"175","author":"Figura","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2026.103158_b0555","unstructured":"Ahmed KA, Kumthekar PU, Pina Y, et al. Radiation Therapy Followed by Intrathecal (IT) Trastuzumab\/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease: Interim Results from a Phase II Multi-Institutional Study (NCT04588545). Presented at: San Antonio Breast Cancer Symposium (SABCS); December 9\u201312, 2025; San Antonio, TX. Accessed December 15, 2025. n.d."},{"key":"10.1016\/j.ctrv.2026.103158_b0560","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12885-018-3994-5","article-title":"Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review","volume":"18","author":"Ricciardi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103158_b0565","doi-asserted-by":"crossref","first-page":"PS11","DOI":"10.1158\/1538-7445.SABCS23-PS11-05","article-title":"Abstract PS11-05: trastuzumab deruxtecan in patients with HER2[+] or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis: results from cohort 5 of the DEBBRAH study","volume":"84","author":"Batista","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103158_b0570","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41523-023-00519-0","article-title":"Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan","volume":"9","author":"Alder","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103158_b0575","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2021.39.15_suppl.1044","volume":"39","author":"Stringer-Reasor","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0580","doi-asserted-by":"crossref","first-page":"745","DOI":"10.6004\/jnccn.2022.7006","article-title":"Response of leptomeningeal metastasis of breast cancer with a HER2\/neu activating variant to tucatinib: a case report","volume":"20","author":"Yan","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2026.103158_b0585","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s43018-026-01120-7","article-title":"Tucatinib\u2013trastuzumab\u2013capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results","volume":"7","author":"Murthy","year":"2026","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ctrv.2026.103158_b0590","article-title":"P14.42 Neratinib for treatment of leptomeningeal metastases from HER2-positive breast cancer in extended access program: preliminary results","volume":"23","author":"Pellerino","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2026.103158_b0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104558","article-title":"Brain imaging screening in metastatic breast cancer: patients\u2019 and physicians\u2019 perspectives","author":"Matos","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2026.103158_b0600","unstructured":"S\u00e1nchez-Bayona R, Cobo S, Kubeczko M, et al. Development of the HER2DX Predictor of Brain Metastasis in Advanced HER2-Positive Breast Cancer Treated with First-Line THP. Poster presented at: San Antonio Breast Cancer Symposium (SABCS); December 9\u201312, 2025; San Antonio, TX. Accessed 15\/12\/2025. n.d."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:47:00Z","timestamp":1781059620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":124,"alternative-id":["S0305737226000721"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103158","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central nervous system and leptomeningeal metastases in patients with HER2-positive breast cancer: A comprehensive review and therapeutic algorithm proposal","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103158"}}